Find Funding Opportunities

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS) invite new (type 1) and renewal (type 2) applications for the Autism Centers of Excellence: Networks Program, hereafter termed ACE Networks. Each ACE Network will consist of a multi-site project focusing on a specific topic of research for R01 support through this FOA. The ACE Networks will focus on supporting the broad research goals of the Interagency Coordinating Committee Strategic Plan for ASD Research (http://iacc.hhs.gov/strategic-plan/2011/index.shtml). Each ACE Network will submit one R01 application that includes subawardss to the collaborating sites. A companion FOA (RFA-HD-12-195) invites applications for ACE Centers supported by the P50 mechanism.

The National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Neurological Disorders and Stroke (NINDS) invite research grant applications focusing on effective interventions that will provide sound scientific evidence for expanding sustainable blood pressure prevention and control programs in low and middle income countries (LMICs) at the local, regional, and national level.

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

This FOA provides for planning grants for clinical trials related to type 1 diabetes. It is expected that these planning grants will lead to clinical trials to test interventions designed to improve glycemic control and/or to treat or reduce diabetes complications. The intent of this initiative is to improve the management and treatment of individuals with type 1 diabetes in the United States. If successful, the results of the future clinical trials should be of practical importance to clinical management and applicable immediately. The purpose of this FOA is not to validate new technologies or test new therapeutics.

CIDR high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes that contribute to human health and disease. The services provided through CIDR focus primarily on needs that cant be readily handled by individual investigator laboratories.CIDR provides the most up-to-date platforms and services. This is an NIH-wide initiative that is managed by NHGRI.Information about the current services offered can be accessed via: http://www.cidr.jhmi.edu.

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for a limited competition Funding Opportunity Announcement (FOA) utilizing a Cooperative Agreement (U24) to provide continuing support for consortia originally funded through the American Recovery and Reinvestment Act of 2009 (ARRA) to develop well characterized, broadly available induced pluripotent stem cell (iPSC) resources for neurodegenerative diseases. A primary goal of this new initiative is to facilitate the scientific evaluation of iPSC resources for drug discovery purposes and to increase the number of lines, types of mutations, reporter modifications, maintenance and differentiation protocols and cell line characterization that are broadly available to the community as research resources. This Initiative is intended to be a partnership with government, non-government organizations and pharmaceutical companies interested in advancing drug discovery efforts for neurodegenerative diseases.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three, four, or five years of salary support and protected time for newly independent (see IC provisions) scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. Prospective candidates are encouraged to contact the relevant Institute or Center (IC) staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates or equivalent who are typically at the Associate Professor level or the equivalent (see Section III. Eligible Individuals) for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (Parent K23). Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts..